GLIA Diagnostics — Making the Invisible Injury Visible
A rapid POC diagnostic platform for TBI/concussion using proprietary microRNA biomarkers.
A rapid POC diagnostic platform for TBI/concussion using proprietary microRNA biomarkers.
GLIA Diagnostics Pty Ltd is an Australian biotechnology company transforming how traumatic brain injury (TBI)/mild TBI (mTBI/concussion) are assessed and managed. TBI is a leading cause of death and disability worldwide, yet current clinical tools are often subjective and inadequate. GLIA is developing a portable, point-of-care (POC) diagnostic system that delivers objective, biologically grounded insight from a simple finger-stick blood sample in minutes. Our platform combines validated microRNA (miRNA) biomarkers with intuitive analytics to support rapid clinical decisions, longitudinal monitoring, and improved outcomes across healthcare, sport, and defence settings.
ITraumatic brain injury is often under-diagnosed due to limited objective tools. GLIA’s solution addresses this gap by providing clinicians, medics, and carers with real-time biological feedback that enhances triage, treatment, and recovery tracking. Our technology is built to be robust, scalable, and suited to emergency departments, athletic programs, military operations, and remote medicine.
Proprietary microRNA Biomarkers
Our biomarkers capture cellular injury signals missed by traditional assessments, offering better specificity and longitudinal relevance.
Point-of-Care Platform
Designed for rapid, scalable use with minimal training — empowering frontline decision-making and enhancing patient safety.
Regulatory & Clinical Validation
GLIA is advancing through rigorous development and validation pathways aligned to international regulatory standards.
This video provides an overview of GLIA's TBI diagnostic testing technology.
Sign up to hear from us.
Mosman, New South Wales, Australia
Open today | 09:00 am – 05:00 pm |
Monday - Friday: 9:00am - 5:00pm
Saturday - Sunday: Closed